These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 26633646)
1. Systemic Medical Treatment in Men with Metastatic Castration-Resistant Prostate Cancer: Recommendations for Daily Routine. Herden J; Heidegger I; Paffenholz P; Porres D Oncol Res Treat; 2015; 38(12):654-68. PubMed ID: 26633646 [TBL] [Abstract][Full Text] [Related]
3. Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents. Bahl A; Masson S; Birtle A; Chowdhury S; de Bono J Cancer Treat Rev; 2014 Feb; 40(1):170-7. PubMed ID: 23958310 [TBL] [Abstract][Full Text] [Related]
4. Treatment options in castration-resistant prostate cancer: current therapies and emerging docetaxel-based regimens. Saad F; Miller K Urol Oncol; 2014 Feb; 32(2):70-9. PubMed ID: 23506965 [TBL] [Abstract][Full Text] [Related]
5. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer. Maughan BL; Xhou XC; Suzman DL; Nadal R; Bassi S; Schweizer MT; Antonarakis ES Prostate; 2015 Nov; 75(15):1814-20. PubMed ID: 26306637 [TBL] [Abstract][Full Text] [Related]
6. Metastatic castration resistant prostate cancer: current strategies of management in the Middle East. Bazarbashi S; Bachour M; Bulbul M; Alotaibi M; Jaloudi M; Jaafar H; Mukherji D; Farah N; Alrubai T; Shamseddine A Crit Rev Oncol Hematol; 2014 Apr; 90(1):36-48. PubMed ID: 24289901 [TBL] [Abstract][Full Text] [Related]
7. Improvement in survival and quality of life with new therapeutic agents in metastatic castration-resistant prostate cancer: comparison among the results. Recine F; Ceresoli GL; Baciarello G; Cerbone L; Calabrò F Q J Nucl Med Mol Imaging; 2015 Dec; 59(4):400-10. PubMed ID: 26337241 [TBL] [Abstract][Full Text] [Related]
8. The economics of abiraterone acetate for castration-resistant prostate cancer. Dellis A; Papatsoris AG Expert Rev Pharmacoecon Outcomes Res; 2014 Apr; 14(2):175-9. PubMed ID: 24564607 [TBL] [Abstract][Full Text] [Related]
10. Castration-resistant prostate cancer: from new pathophysiology to new treatment. Sridhar SS; Freedland SJ; Gleave ME; Higano C; Mulders P; Parker C; Sartor O; Saad F Eur Urol; 2014 Feb; 65(2):289-99. PubMed ID: 23957948 [TBL] [Abstract][Full Text] [Related]
11. Emerging agents for the therapy of advanced prostate cancer. Hathaway AR; Baker MK; Sonpavde G Future Oncol; 2015; 11(20):2775-87. PubMed ID: 26367474 [TBL] [Abstract][Full Text] [Related]
12. [Metastatic castration-resistant prostate cancer : Clinical data, new treatment options and therapy monitoring]. Miller K; Albers P; Eichenauer R; Geiges G; Grimm MO; König F; Mickisch G; Pfister D; Schwentner C; Suttmann H; Zastrow S Urologe A; 2016 Sep; 55(9):1206-12. PubMed ID: 27411995 [TBL] [Abstract][Full Text] [Related]
13. Austrian recommendations on Targeted Hormone Therapy for metastatic, castration-resistant prostate cancer. Ponholzer A; Loidl W; Bektic J; Dorfinger K; Hruby S; Jeschke K; Kramer G; Krause S; Ludvik G; Remzi M; Roider M; Stoiber F Wien Klin Wochenschr; 2016 Feb; 128(3-4):156-63. PubMed ID: 26831188 [TBL] [Abstract][Full Text] [Related]
14. Managing Metastatic Castration-Resistant Prostate Cancer in the Pre-chemotherapy Setting: A Changing Approach in the Era of New Targeted Agents. Zafeiriou Z; Jayaram A; Sharp A; de Bono JS Drugs; 2016 Mar; 76(4):421-30. PubMed ID: 26873496 [TBL] [Abstract][Full Text] [Related]
15. [New therapy concepts for castration-resistant prostate cancer: between hormone manipulation, targeted therapy and chemotherapy]. Kübler H; Miller K Urologe A; 2013 Nov; 52(11):1517-8, 1520-1, 1524-6 passim. PubMed ID: 24166056 [TBL] [Abstract][Full Text] [Related]